BUZZ-India's Sun Pharma set for worst day in nearly 6 years on report of $12 bln Organon bid

Reuters04-10
BUZZ-India's Sun Pharma set for worst day in nearly 6 years on report of $12 bln Organon bid

** Sun Pharmaceutical Industries SUN.NS down 4.8% to 1,635 rupees; set for worst day since August 31, 2020

** Stock top loser on benchmark Nifty 50 .NSEI, Nifty 500 .NIFTY500 indexes

** Sun Pharma has decided to proceed with binding offer of $12 billion to acquire U.S.-based Organon OGN.N, newspaper The Economic Times reports, citing sources

** ICICI Securities says deal would value OGN at ~2x its 2026 expected sales when it's facing competition across three operating segments of women's health, biosimilars, established brands

** Adds SUN expected to assume $8 billion debt (as part of deal)

** Notes prime facie, target seems to be fraught with challenges

* Both cos yet to respond to Reuters email seeking comment

** More than 4.7 million SUN shares traded, ~1.6x the 30-day avg vol

** SUN rated "buy" on avg; median PT at 1,978 rupees, per data compiled by LSEG

** YTD, SUN down 5%

(Reporting by Vivek Kumar M)

((VivekKumar.M@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment